Elliott Amanda Floetke, Horgas Ann L
Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-0009, USA.
Nurs Res. 2009 Mar-Apr;58(2):140-5. doi: 10.1097/NNR.0b013e318199b599.
Analgesic trials have been advocated as a means to reduce pain in persons with dementia (PWDs), but few systematic studies have been reported.
The aims of this study were to assess the feasibility of conducting a repeated-measures study of pain in PWDs and to investigate the effect of the scheduled dosing of acetaminophen in reducing observable pain behaviors in community-dwelling PWDs.
A within-subjects ABAB withdrawal design was utilized in this pilot study, with data collected daily for 24 days. Two baseline (nontreatment) phases were alternated with two treatment phases to examine the effects of scheduled extended-release acetaminophen (1.3 g every 8 hr) in reducing pain-related behaviors. The sample consisted of 3 participants (2 women; mean age = 85 years; mean Mini-Mental State Examination score = 11.7) with osteoarthritis. Pain behaviors were measured during a daily, videotaped activity-based protocol designed to elicit pain.
The results indicate that it is possible to conduct this type of intensive, daily pain investigation in community-dwelling older adults with moderate to severe dementia. Behavioral indicators of pain varied daily and in response to treatment. During treatment phases, pain behaviors decreased in both frequency and duration relative to the control and baseline phases and increased when treatment was withdrawn.
Acetaminophen use reduced pain behaviors associated with musculoskeletal pain in this sample of PWDs. This provides preliminary evidence that acetaminophen is an effective pain reliever for this population. In addition, the study supports the use of a within-subjects design to examine daily variability in pain behaviors and to demonstrate treatment effects in PWDs.
镇痛试验被认为是减轻痴呆症患者(PWDs)疼痛的一种方法,但鲜有系统性研究报道。
本研究旨在评估对痴呆症患者进行疼痛重复测量研究的可行性,并调查按计划服用对乙酰氨基酚对减少社区居住痴呆症患者可观察到的疼痛行为的效果。
本试点研究采用受试者内ABAB撤药设计,每天收集24天的数据。两个基线(非治疗)阶段与两个治疗阶段交替进行,以检验按计划服用缓释对乙酰氨基酚(每8小时1.3克)对减少疼痛相关行为的效果。样本包括3名骨关节炎患者(2名女性;平均年龄 = 85岁;简易精神状态检查表平均得分 = 11.7)。在一项旨在引发疼痛的基于日常录像活动的方案中测量疼痛行为。
结果表明,对社区居住的中重度痴呆老年人进行这种密集的每日疼痛调查是可行的。疼痛的行为指标每天都有变化,并对治疗有反应。在治疗阶段,与对照和基线阶段相比,疼痛行为的频率和持续时间均有所下降,撤药时则增加。
在这个痴呆症患者样本中,使用对乙酰氨基酚减少了与肌肉骨骼疼痛相关的疼痛行为。这提供了初步证据,表明对乙酰氨基酚对该人群是一种有效的止痛药。此外,该研究支持使用受试者内设计来检查疼痛行为的每日变异性,并证明对痴呆症患者的治疗效果。